Tag:
JTT-305
Latest Headlines
Latest Headlines
Merck, Japan Tobacco ink osteoporosis deal
Merck has signed an agreement with Japan Tobacco to develop and commercialize JTT-305, an investigational oral osteoanabolic drug. Japan Tobacco gets an undisclosed upfront payment and could receive
